WO1999003987A3 - Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie - Google Patents

Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie Download PDF

Info

Publication number
WO1999003987A3
WO1999003987A3 PCT/FR1998/001570 FR9801570W WO9903987A3 WO 1999003987 A3 WO1999003987 A3 WO 1999003987A3 FR 9801570 W FR9801570 W FR 9801570W WO 9903987 A3 WO9903987 A3 WO 9903987A3
Authority
WO
WIPO (PCT)
Prior art keywords
respiratory virus
antibodies
diagnosis
therapy
useful
Prior art date
Application number
PCT/FR1998/001570
Other languages
English (en)
Other versions
WO1999003987A2 (fr
Inventor
Thien Ngoc Nguyen
Ultan Power
Liliane Goestch
Alain Beck
Original Assignee
Pf Medicament
Thien Ngoc Nguyen
Ultan Power
Liliane Goestch
Alain Beck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament, Thien Ngoc Nguyen, Ultan Power, Liliane Goestch, Alain Beck filed Critical Pf Medicament
Priority to AU88123/98A priority Critical patent/AU756110B2/en
Priority to EP98939703A priority patent/EP1003851A2/fr
Priority to BR9810907-3A priority patent/BR9810907A/pt
Priority to CA002296736A priority patent/CA2296736A1/fr
Priority to JP2000503193A priority patent/JP2001510039A/ja
Publication of WO1999003987A2 publication Critical patent/WO1999003987A2/fr
Publication of WO1999003987A3 publication Critical patent/WO1999003987A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un anticorps polyclonal ou monoclonal dirigé contre un épitope de la protéine G du VRS correspondant à une séquence choisie parmi l'une des séquences peptidiques comprises respectivement entre les résidus d'acides aminés 150-159, 176-189, 194-207 et 155-176 de la séquence totale de la protéine G du VRS A ou B, ou des séquences présentant au moins 98 % d'homologie.
PCT/FR1998/001570 1997-07-17 1998-07-17 Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie WO1999003987A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU88123/98A AU756110B2 (en) 1997-07-17 1998-07-17 Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy
EP98939703A EP1003851A2 (fr) 1997-07-17 1998-07-17 Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
BR9810907-3A BR9810907A (pt) 1997-07-17 1998-07-17 Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
CA002296736A CA2296736A1 (fr) 1997-07-17 1998-07-17 Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
JP2000503193A JP2001510039A (ja) 1997-07-17 1998-07-17 診断および治療に有用な呼吸器多核体ウイルスエピトープならびにそれらを含んでなる抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR97/09079 1997-07-17
FR9709079A FR2766192B1 (fr) 1997-07-17 1997-07-17 Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie

Publications (2)

Publication Number Publication Date
WO1999003987A2 WO1999003987A2 (fr) 1999-01-28
WO1999003987A3 true WO1999003987A3 (fr) 1999-04-08

Family

ID=9509314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1998/001570 WO1999003987A2 (fr) 1997-07-17 1998-07-17 Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie

Country Status (8)

Country Link
EP (1) EP1003851A2 (fr)
JP (1) JP2001510039A (fr)
CN (1) CN1264425A (fr)
AU (1) AU756110B2 (fr)
BR (1) BR9810907A (fr)
CA (1) CA2296736A1 (fr)
FR (1) FR2766192B1 (fr)
WO (1) WO1999003987A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790959B1 (fr) * 1999-03-15 2003-06-27 Pf Medicament Utilisation de fractions membranaires bacteriennes a effet adjuvant, leurs procedes de preparation et composition pharmaceutique les contenant
GB9920000D0 (en) * 1999-08-25 1999-10-27 Imp Cancer Res Tech Polypeptides
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
EP1174506A1 (fr) * 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek Le peptide C-terminal de Erns et ses analogues
FR2819810B1 (fr) * 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
SK287965B6 (sk) * 2002-02-05 2012-07-03 Geymonat S. P. A. Process for extracting and purifying the recombinant Placental Growth Factor and Placental Growth Factor in active form
CN100528896C (zh) * 2004-02-03 2009-08-19 中国人民解放军军事医学科学院毒物药物研究所 用于预防、诊断和治疗呼吸道合胞病毒感染的嵌合抗原及其抗体
WO2006023029A2 (fr) * 2004-06-16 2006-03-02 The Johns Hopkins University Region riche en cysteine du virus respiratoire syncytial et procedes d'utilisation associes
CN101130765B (zh) * 2006-08-21 2011-04-06 北京阿斯可来生物工程有限公司 呼吸道合胞病毒检测试剂盒
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv
CA2770304C (fr) * 2009-08-04 2019-11-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenes anti-vrs et procedes d'immunisation
CN103163302B (zh) * 2011-12-10 2015-06-03 河北菲尼斯生物技术有限公司 一种采用定向交叉偶联技术制备的短肽抗体试剂盒
CN106749555A (zh) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432435A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106397547A (zh) * 2016-11-28 2017-02-15 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432436A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432438A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432437A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106432439A (zh) * 2016-11-28 2017-02-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106518988A (zh) * 2016-11-28 2017-03-22 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN106749556A (zh) * 2016-11-28 2017-05-31 烟台偌帝生物工程有限公司 一种牛呼吸道胞合体病毒抗原蛋白
CN112409481B (zh) * 2020-12-01 2024-03-26 福州捷赫生物科技有限公司 抗p40蛋白单克隆抗体、细胞系及其制备方法和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002935A1 (fr) * 1987-09-29 1989-04-06 Praxis Biologics, Inc. Virus syncytial respiratoire: vaccins et dosages de diagnostic
WO1992020805A1 (fr) * 1991-05-13 1992-11-26 Pierre Fabre Medicament Adn recombine codant pour un peptide signal, polypeptide d'interaction et sequence d'ancrage de membrane
FR2718452A1 (fr) * 1994-04-06 1995-10-13 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
WO1996006112A1 (fr) * 1994-08-25 1996-02-29 Instituut Voor Veehouderij En Diergezondheid (Id-Dlo) Peptides antigeniques derives de la proteine g du virus respiratoire syncytial (rsv) utilises pour le diagnostic specifique d'un type ou d'un sous-type d'une infection a rsv
WO1996014409A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Production de peptides recombinants, analogues de peptides naturels hydrophobes
WO1996014415A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
WO1996014416A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
WO1996014418A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Proteine g du virus respiratoire syncytial exprimee sur membrane bacterienne
WO1997046581A1 (fr) * 1996-06-05 1997-12-11 Biomolecular Research Institute Ltd. Peptides viraux presentant une homologie structurelle avec la proteine g du virus respiratoire syncytial bovin

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002935A1 (fr) * 1987-09-29 1989-04-06 Praxis Biologics, Inc. Virus syncytial respiratoire: vaccins et dosages de diagnostic
WO1992020805A1 (fr) * 1991-05-13 1992-11-26 Pierre Fabre Medicament Adn recombine codant pour un peptide signal, polypeptide d'interaction et sequence d'ancrage de membrane
FR2718452A1 (fr) * 1994-04-06 1995-10-13 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
WO1995027787A1 (fr) * 1994-04-06 1995-10-19 Pierre Fabre Medicament Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
WO1996006112A1 (fr) * 1994-08-25 1996-02-29 Instituut Voor Veehouderij En Diergezondheid (Id-Dlo) Peptides antigeniques derives de la proteine g du virus respiratoire syncytial (rsv) utilises pour le diagnostic specifique d'un type ou d'un sous-type d'une infection a rsv
WO1996014409A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Production de peptides recombinants, analogues de peptides naturels hydrophobes
WO1996014415A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
WO1996014416A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
WO1996014418A1 (fr) * 1994-11-07 1996-05-17 Pierre Fabre Medicament Proteine g du virus respiratoire syncytial exprimee sur membrane bacterienne
WO1997046581A1 (fr) * 1996-06-05 1997-12-11 Biomolecular Research Institute Ltd. Peptides viraux presentant une homologie structurelle avec la proteine g du virus respiratoire syncytial bovin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIMARD C ET AL: "EVIDENCE THAT THE AMINO ACID REGION 124-203 OF GLYCOPROTEIN G FROM THE RESPIRATORY SYNCYTIAL VIRUS (RSV) CONSTITUES A MAJOR PART OF THE POLYPEPTIDE DOMAIN THAT IS INVOLVED IN THE PROTECTION AGAINST RSV INFECTION", ANTIVIRAL RESEARCH, vol. 28, no. 4, 1 January 1995 (1995-01-01), pages 303 - 315, XP000565377 *
TRUDEL ET AL.: "PROTECTION OF BALB/c MICE FROM RESPIRATORY SYNCYTIAL VIRUS INFECTION BY IMMUNIZATION WITH A SYNTHETIC PEPTIDE DERIVED FROM THE G GLYCOPROTEIN", VIROLOGY, vol. 185, 1991, pages 749 - 757, XP002062551 *

Also Published As

Publication number Publication date
JP2001510039A (ja) 2001-07-31
FR2766192A1 (fr) 1999-01-22
AU756110B2 (en) 2003-01-02
WO1999003987A2 (fr) 1999-01-28
AU8812398A (en) 1999-02-10
FR2766192B1 (fr) 2001-07-13
BR9810907A (pt) 2000-08-01
CN1264425A (zh) 2000-08-23
EP1003851A2 (fr) 2000-05-31
CA2296736A1 (fr) 1999-01-28

Similar Documents

Publication Publication Date Title
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
WO1995029193A3 (fr) Antigenes du melanome
DE69938054D1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
MY145191A (en) Human antibodies that bind human il-12 and methods for producing
CA2054798A1 (fr) Peptides specifique du vhc, leurs agents et leur utilisation
CA2172376A1 (fr) Anticorps diriges contre le cd40
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
EP0673255A4 (fr) Anticorps monoclonal se liant specifiquement a l'endothelium vasculaire tumoral.
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
WO2003048194A3 (fr) Peptide ou proteine contenant une boucle c'-d de la famille de recepteurs cd28
WO1996021734A3 (fr) Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
HUP0103152A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
WO1998033810A3 (fr) Peptides appauvris en cysteine reconnus par des lymphocytes cytotoxiques limites par a3 et leurs mises en application
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
WO2003106478A3 (fr) Anticorps se liant a l'integrine alphae
WO2003011907A3 (fr) Recepteur, son utilisation, et anticorps de souris
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
WO1996040250A3 (fr) Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation
CA2134080A1 (fr) Anticorps igm reagissant a la protamine
EP0816498A3 (fr) Récepteur pour acide aminé excitateur et acides nucléiques liés
CA2140091A1 (fr) Peptides et antiserums pour la detection de la cyclooxygenase-1 et de la cyclooxygenase-2 humaines
EP0915158A3 (fr) Améliorations en ce qui concerne la détection de Salmonella
EP0918796A4 (fr) Anticorps monoclonal permettant d'agglutiner e. coli possedant une proteine de la famille cs4-cfa/i

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98807304.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2296736

Country of ref document: CA

Ref document number: 2296736

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09462918

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998939703

Country of ref document: EP

Ref document number: 88123/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998939703

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 88123/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998939703

Country of ref document: EP